$2.17 Million in Sales Expected for Xeris Pharmaceuticals Inc (NASDAQ:XERS) This Quarter

Wall Street analysts predict that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will announce $2.17 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Xeris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $2.70 million. Xeris Pharmaceuticals reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 600%. The company is expected to announce its next earnings results on Tuesday, August 4th.

According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current financial year, with estimates ranging from $12.30 million to $18.10 million. For the next financial year, analysts anticipate that the firm will post sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.89) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative return on equity of 323.82% and a negative net margin of 3,100.00%. The business had revenue of $1.68 million during the quarter, compared to the consensus estimate of $1.82 million.

A number of brokerages recently issued reports on XERS. Zacks Investment Research raised Xeris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a report on Saturday. Mizuho reaffirmed a “buy” rating and issued a $14.00 price target on shares of Xeris Pharmaceuticals in a report on Tuesday, May 26th. Finally, ValuEngine raised Xeris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 30th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $12.50.

XERS traded up $0.17 on Monday, reaching $2.68. The company’s stock had a trading volume of 3,332,848 shares, compared to its average volume of 787,454. The stock has a 50 day moving average of $4.64 and a two-hundred day moving average of $4.49. The company has a quick ratio of 4.72, a current ratio of 4.82 and a debt-to-equity ratio of 2.16. The company has a market capitalization of $94.35 million, a price-to-earnings ratio of -0.56 and a beta of 2.10. Xeris Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.94.

In other news, insider Paul R. Edick acquired 33,000 shares of Xeris Pharmaceuticals stock in a transaction on Friday, May 8th. The stock was bought at an average price of $3.54 per share, for a total transaction of $116,820.00. Following the completion of the purchase, the insider now owns 95,493 shares in the company, valued at $338,045.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Patrick Shannon, Jr. acquired 22,000 shares of Xeris Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $3.55 per share, with a total value of $78,100.00. Following the purchase, the insider now owns 117,493 shares of the company’s stock, valued at approximately $417,100.15. The disclosure for this purchase can be found here. 5.95% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. M&T Bank Corp lifted its position in Xeris Pharmaceuticals by 20.8% during the fourth quarter. M&T Bank Corp now owns 20,543 shares of the company’s stock worth $145,000 after buying an additional 3,540 shares during the period. Deutsche Bank AG raised its holdings in shares of Xeris Pharmaceuticals by 40.7% during the 1st quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock valued at $27,000 after buying an additional 3,942 shares during the period. American International Group Inc. raised its holdings in shares of Xeris Pharmaceuticals by 26.3% during the 1st quarter. American International Group Inc. now owns 21,090 shares of the company’s stock valued at $41,000 after buying an additional 4,394 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Xeris Pharmaceuticals by 8.7% during the 4th quarter. Bank of New York Mellon Corp now owns 83,352 shares of the company’s stock valued at $588,000 after buying an additional 6,648 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Xeris Pharmaceuticals during the 1st quarter valued at about $71,000. Institutional investors and hedge funds own 62.48% of the company’s stock.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Article: Why do analysts give a neutral rating?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.